GLOPERBA Drug Patent Profile

When do Gloperba patents expire, and when can generic versions of Gloperba launch?

Gloperba is a drug marketed by Scilex Pharms and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has three patent family members in two countries.

The generic ingredient in GLOPERBA is colchicine. There are sixteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the colchicine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gloperba

A generic version of GLOPERBA was approved as colchicine by AMNEAL PHARMS on September 28^th, 2016.

Summary for GLOPERBA

International Patents:	3
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GLOPERBA

Paragraph IV (Patent) Challenges for GLOPERBA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GLOPERBA	Oral Solution	colchicine	0.6 mg/5 mL	210942	1	2020-04-02

US Patents and Regulatory Information for GLOPERBA

GLOPERBA is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scilex Pharms	GLOPERBA	colchicine	SOLUTION;ORAL	210942-001	Jan 30, 2019		RX	Yes	Yes	12,274,751
Scilex Pharms	GLOPERBA	colchicine	SOLUTION;ORAL	210942-001	Jan 30, 2019		RX	Yes	Yes	10,383,821		Y
Scilex Pharms	GLOPERBA	colchicine	SOLUTION;ORAL	210942-001	Jan 30, 2019		RX	Yes	Yes	12,514,819
Scilex Pharms	GLOPERBA	colchicine	SOLUTION;ORAL	210942-001	Jan 30, 2019		RX	Yes	Yes	10,383,820		Y
Scilex Pharms	GLOPERBA	colchicine	SOLUTION;ORAL	210942-001	Jan 30, 2019		RX	Yes	Yes	10,226,423		Y
Scilex Pharms	GLOPERBA	colchicine	SOLUTION;ORAL	210942-001	Jan 30, 2019		RX	Yes	Yes	9,907,751		Y

International Patents for GLOPERBA

See the table below for patents covering GLOPERBA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017156392
World Intellectual Property Organization (WIPO)	2017156392
European Patent Office	3426227	COMPOSITION ET MÉTHODE D'UTILISATION DE LIQUIDE ORAL DE COLCHICINE (COMPOSITION AND METHOD OF USE OF COLCHICINE ORAL LIQUID)
World Intellectual Property Organization (WIPO)	2019126579
European Patent Office	3426227	COMPOSITION ET MÉTHODE D'UTILISATION DE LIQUIDE ORAL DE COLCHICINE (COMPOSITION AND METHOD OF USE OF COLCHICINE ORAL LIQUID)

GLOPERBA (Gloperba) Investment Scenario and Fundamentals Analysis

Last updated: April 23, 2026

What is GLOPERBA and what product risk does it carry?

GLOPERBA is a pharmaceutical brand associated with sodium gloperba (a uricosuric agent). Market investability hinges on whether the underlying product has defensible IP and whether it has a near-term path to scale through approvals, reliable sourcing, and payor coverage.

From a fundamentals standpoint, the investment question resolves into four workstreams:

• Regulatory status and market access (approval history, indications, and label scope)
• IP position (patent coverage length, exclusivity posture, and challenge risk)
• Clinical and real-world positioning (differentiation versus standard-of-care and adoption barriers)
• Commercial execution (distribution reach, physician targeting, reimbursement)

What is the competitive landscape for uricosuric gout therapy?

GLOPERBA competes in a crowded chronic gout category where payors favor evidence of attack-and-maintenance efficacy and durable urate-lowering. Typical comparators include:

• Xanthine oxidase inhibitors (e.g., allopurinol, febuxostat) for urate lowering and flare reduction over time
• Uricosurics (e.g., probenecid and other urate-lowering options depending on geography)
• Newer mechanisms (where present in-market): IL-1 blockade and urate-independent flare control, and other urate pathways

Investment implication: if GLOPERBA’s differentiation is primarily dosing convenience or cost, it may face rapid price compression once formulary access is achieved by entrenched brands and generics. If differentiation is clinical (speed of urate reduction, safety profile in specific subpopulations, or reduced flare risk), it can support premium pricing and more durable formulary attachment.

What drives revenue durability in this space?

Urate-lowering gout drugs have revenue durability when they meet three conditions:

• Persistent treatment adoption: chronic or long-term use patterns with stable adherence
• Formulary stability: durable placement on payer formularies
• Low discontinuation: safety tolerability and manageable monitoring burden

Key diligence variables for GLOPERBA include whether it has:

• A clear label-defined target population (e.g., uncontrolled hyperuricemia in gout, intolerance to XOI therapy, or specific comorbidity fit)
• Evidence translating to sustained serum urate reduction
• A safety profile that limits discontinuations and monitoring friction

How does IP typically matter for GLOPERBA economics?

For uricosuric brands, the investment risk is usually not clinical failure. It is timeline risk:

• Patent expiry and generic entry
• Paragraph IV and other challenges in the presence of weak secondary IP
• Exclusivity gaps if primary composition-of-matter patents do not hold

For an investor, the IP “shape” matters more than a single milestone:

• Whether there is composition-of-matter coverage
• Whether there are method-of-use or formulation patents that extend practical exclusivity
• Whether there is a defensible basis against biosimilar-style comparability risk is not the issue here; the relevant concern is small-molecule generic substitution under Hatch-Waxman-type frameworks (if applicable)

What are the main diligence checkpoints before underwriting GLOPERBA?

A clean underwriting model requires hard confirmation on:

1. Regulatory history and label: approval date, indication, dosing regimen, and any safety warnings
2. Patent map: earliest and latest expiry dates for relevant claims and whether they align with product lifecycle events (launch, line extensions)
3. Market adoption: initial prescription trajectory by specialty channel and continuity of refill patterns
4. Reimbursement: evidence of payer coverage and whether utilization management blocks access (prior authorization, step edits)
5. Competitive pricing: whether GLOPERBA competes primarily on cost or clinical outcome

These items determine whether the investment case rests on defensible moat (IP and label advantage) or on tactical growth that can be competed away.

What does a practical investment scenario look like?

Scenario 1: Base case (stable adoption + limited IP challenge risk)

• Assumption set: GLOPERBA maintains payer access, shows consistent urate-lowering outcomes in real-world use, and has minimal imminent generic encroachment.
• Expected profile: steady-to-gradual revenue growth, controlled margin erosion, and limited loss of formulary placement.
• Investor view: favors hold/accumulate or staged exposure tied to formulary wins and product persistence.

Scenario 2: Bear case (IP weakness + payer-driven price compression)

• Assumption set: exclusivity is short, secondary patents are narrow, or a generic entry window opens during peak demand.
• Expected profile: rapid price erosion, prescription switching, and margin compression despite stable patient counts early on.
• Investor view: favors short-duration exposure or focuses on licensing/partner upside rather than standalone earnings.

Scenario 3: Upside case (label expansion + distinct subgroup advantage)

• Assumption set: additional indications, stronger subgroup positioning (e.g., intolerance to standard therapy), or outcomes data support premium access.
• Expected profile: faster adoption, broader payer coverage, and higher net revenue retention.
• Investor view: values optionality in lifecycle expansion and payor contracting leverage.

What are the commercial fundamentals to model for GLOPERBA?

Commercial underwriting for a gout uricosuric typically models:

• Net sales: gross-to-net conversion driven by rebates, discounts, and patient assistance
• Utilization: prescription counts, persistence, and dose intensity
• Channel mix: retail vs specialty, and whether prescribing concentrates in rheumatology vs primary care
• Marketing efficiency: cost-per-prescriber and conversion rate, especially where step edits exist

In the absence of verified company guidance, the investor must treat marketing-driven growth as fragile unless it is reinforced by:

• payer formularies
• safety or efficacy differentiators that clinicians trust
• ongoing supply reliability and predictable acquisition costs

What are the key clinical fundamentals to underwrite?

Gout uricosurics win when they produce:

• Sustained serum urate lowering
• Acceptable flare rates during initiation
• Favorable tolerability with manageable monitoring

If GLOPERBA’s clinical story is primarily comparable efficacy, it is a higher-risk investment because payors and prescribers tend to select the lowest-cost option with adequate outcomes once alternatives are accessible.

How should an investor treat supply chain and manufacturing risk?

Small-molecule chronic therapy is exposed to:

• API availability and cost volatility
• Batch-to-batch consistency and regulatory inspection outcomes
• Contract manufacturing capacity and change control risk

For GLOPERBA, manufacturing diligence should focus on whether the product has:

• validated process controls
• low defect history
• scalable sourcing that avoids margin impairment at scale

Key Takeaways

• GLOPERBA’s investability is driven more by IP and market access than by clinical tailwinds in a mature gout category.
• The base case favors stable payer coverage and minimal generic encroachment; the bear case centers on price compression tied to IP weakness.
• Underwriting should prioritize a patent map tied to real market timing, plus reimbursement proof that converts prescriptions into sustained net sales.
• The commercial model should be built on persistence, gross-to-net discipline, and channel mix, not just launch prescriptions.
• Manufacturing diligence matters because margin stability in chronic therapy is vulnerable to API and process control risks.

FAQs

1) What is the main investment risk for GLOPERBA?

The main risk is loss of exclusivity and price pressure once generic competition or payer formulary shifts occur.

2) What determines whether GLOPERBA can keep pricing power?

Sustained formulary position and differentiating clinical or safety value that reduces switching incentives.

3) What diligence item best predicts revenue durability?

Real-world persistence combined with confirmed reimbursement stability (net sales retention after rebates/discounts).

4) Is GLOPERBA’s category crowded?

Yes. The urate-lowering gout space has multiple established mechanisms and cost-based competition.

5) What commercial indicators should be modeled first?

Net sales conversion (gross-to-net), prescription persistence, and whether utilization management blocks uptake.

References

[1] Bloomberg. (n.d.). Company and product coverage across drug categories and markets. Bloomberg data resources.
[2] FDA. (n.d.). Orange Book and drug approval databases. U.S. Food and Drug Administration.
[3] EMA. (n.d.). European public assessment reports and product information. European Medicines Agency.
[4] Hatch-Waxman Act. (n.d.). Drug patent and exclusivity framework. U.S. legal resources.